Molecular Pathogenesis
The five genes (COL9A1, COL9A2, COL9A3, COMP, and MATN3) in which pathogenic variants cause autosomal dominant multiple epiphyseal dysplasia (MED) encode three structural macromolecules of the cartilage extracellular matrix (type IX collagen, cartilage oligomeric matrix protein, and matrilin-3) [Unger & Hecht 2001, Briggs & Chapman 2002]. These proteins interact with each other and with type II collagen both in vitro [Rosenberg et al 1998, Holden et al 2001, Thur et al 2001, Mann et al 2004, Budde et al 2005, Wagener et al 2005, Fresquet et al 2007, Fresquet et al 2008, Fresquet et al 2010] and in vivo [Budde et al 2005, Blumbach et al 2008, Zaucke & Grässel 2009].
Collagen IX Genes
Gene structure. The coding sequence of COL9A1 is organized into 38 exons spanning approximately 90 kb [Pihlajamaa et al 1998]; the coding sequence of COL9A2 and COL9A3 is organized into 32 exons spanning approximately 15 kb and 23 kb, respectively [Paassilta et al 1999]. For a detailed summary of gene and protein information, see Table A, Gene.
Pathogenic variants. Pathogenic variants in COL9A genes cause MED (Table B). All reported MED-associated pathogenic variants are clustered in one of the followng:
The splice donor site of
exon 3 of
COL9A2The splice acceptor site of
exon 3 of
COL9A3The splice acceptor site of
exon 8 of
COL9A1
Both exon 3 pathogenic variants result in exon 3 skipping during RNA splicing; the resulting 36-bp deletion in the mRNA translates to a 12-amino acid in-frame deletion from the encoded protein. The exon 8 splice site pathogenic variant in COL9A1 results in a complex splicing pattern in which exon 8 (75 bp), exon 10 (63 bp), or both exons 8 and 10 (138 bp) are deleted, giving rise to the in-frame deletion of 25, 21, or 49 amino acids. All of the deletions are located in a similar region of the COL3 domain of type IX collagen, demonstrating the importance of this domain [Unger & Hecht 2001, Briggs & Chapman 2002].
Normal gene product. Type IX collagen, a heterotrimer [α1(IX)α2(IX)α3(IX)] of polypeptides encoded by COL9A1, COL9A2, and COL9A3, is an integral component of cartilage and a member of the FACIT (fibril-associated collagen with interrupted triple helix) group of collagens. Type IX collagen has three collagenous (COL) domains separated by non-collagenous (NC) domains. The amino-terminal NC domain (NC4) is encoded entirely by COL9A1. The collagenous domains (COL1-COL3) are separated by four non-collagenous (NC1-NC4) domains. The COL domains closely associate with type II collagen fibrils and are thought to act as a molecular bridge between collagen fibrils and other cartilage matrix components.
Abnormal gene product. The in-frame exon-skipping pathogenic variants in COL9 (see Pathogenic variants) result in deletion of amino acids from the COL3 domain, which may affect its ability to fold correctly or interact with other components of the cartilage extracellular matrix [Fresquet et al 2007].
Studies have confirmed that a COL9A3 pathogenic variant indeed abolishes binding of type IX collagen to matrilin-3 and type II collagen, thus identifying for the first time a molecular consequence of these pathogenic variants [Fresquet et al 2007].
COMP
Gene structure. The coding sequence of COMP is organized into 19 exons spanning approximately 8.5 kb. For a detailed summary of gene and protein information, see Table A, Gene. Exons 8-14 encode the type III repeats and exons 15-19 encode the C-terminal domain (see Normal gene product) [Unger & Hecht 2001, Briggs & Chapman 2002].
Pathogenic variants. All of the pathogenic variants identified in COMP that result in MED are either missense variants or small in-frame deletions and duplications found in the type III repeats (85%) or C-terminal domain (15%) of COMP [Kennedy et al 2005a, Kennedy et al 2005b, Jackson et al 2012]. To date, nearly 100 different pathogenic missense variants have been reported in these two domains.
Small in-frame deletions (p.Arg367_Gly368del and p.Asn386del) and duplication (p.Asp473dup) in the type III repeat region have been reported. Recurrent pathogenic variants in the type III repeat region include p.Asp385Asn and p.Asn523Lys. A number of C-terminal missense variants have been identified; they include p.Asn555Lys, p.Asp605Asn, p.Ser681Cys, p.Arg718Pro, and the recurrent p.Arg718Trp [Kennedy et al 2005a, Jackson et al 2012]. Two variants (p.Thr585Arg and p.Thr585Met) have been shown to result in either mild pseudoachondroplasia or MED, confirming that the two disorders are related. See Table 4.
More recently a putative variant (p.Gly167Glu) has been identified in exon 5 of COMP, which encodes residues of the second epidermal growth factor (EGF)-like repeat of COMP [Jackson et al 2012]. A previous study by Kennedy et al [2005b] demonstrated that approximately 70% of MED-causing variants in COMP reside in exons 10, 11, and 13, a finding confirmed by a recent study [Jackson et al 2012], which also reaffirmed that MED-causing variants are not found in exons 15, 17, and 19 of COMP.
Table 4.
Pathogenic COMP Variants Discussed in This GeneReview
View in own window
DNA Nucleotide Change | Predicted Protein Change | Reference Sequences |
---|
c.500G>A | p.Gly167Glu |
NM_000095.2
NP_000086.2
|
c.1099_1104del | p.Arg367_Gly368del |
c.1153G>A | p.Asp385Asn |
c.1156_1158del | p.Asn386del |
c.1417_1419dup | p.Asp473dup |
c.1569C>G | p.Asn523Lys |
c.1665C>A | p.Asn555Lys |
c.1754C>G | p.Thr585Arg |
c.1754C>T | p.Thr585Met |
c.1813G>A | p.Asp605Asn |
c.2042C>G | p.Ser681Cys |
c.2153G>C | p.Arg718Pro |
c.2152C>T | p.Arg718Trp |
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. COMP is a 550-kd protein of 757 amino acids. It is a pentameric adhesive glycoprotein found predominantly in the extracellular matrix (ECM) of cartilage but also in tendon and ligament. It is a member of the thrombospondin protein family comprising:
The type III repeats bind Ca2+ cooperatively and with high affinity, while the C-terminal globular domain has the ability to interact with both fibrillar (type I, II, and III) and nonfibrillar collagens, such as type IX [Rosenberg et al 1998, Holden et al 2001, Thur et al 2001, Mann et al 2004], and fibronectin [Di Cesare et al 2002].
Abnormal gene product. Pathogenic variants in the type III repeats result in the misfolding of the protein and its retention in the rough endoplasmic reticulum (rER) of chondrocytes, likely resulting in ER stress and an unfolded protein response and cell death [Chen et al 2000, Maddox et al 2000, Unger & Hecht 2001, Kleerekoper et al 2002]. The effect of pathogenic variants in the C-terminal domain is not fully resolved, but these pathogenic variants do not always prevent the secretion of abnormal protein in vitro [Spitznagel et al 2004, Schmitz et al 2006] or in vivo [Piróg-Garcia et al 2007].
Several transgenic mouse models of COMP pathogenic variants have been developed to study disease mechanisms in vivo [Schmitz et al 2008, Posey et al 2009, Suleman et al 2012]. Although the majority of these models have the same pseudoachondroplasia-causing COMP pathogenic variant (i.e., Asp469del) they nonetheless provide some insight into the disease mechanisms of MED caused by similar COMP pathogenic variants. For example, mutated COMP is retained in the ER of chondrocytes, causing reduced chondrocyte proliferation and increased/dysregulated cell death [Suleman et al 2012].
In addition, the generation of a mouse model of MED-pseudoachondroplasia with a p.Thr585Met pathogenic variant in the C-terminal domain has provided novel insight into disease mechanisms in vivo. Mutated COMP protein is efficiently secreted from the rER of chondrocytes, but still elicits a mild unfolded protein response. This ultimately results in decreased chondrocyte proliferation and increased and spatially dysregulated apoptosis that is possibly mediated by CHOP [Piróg-Garcia et al 2007]. More recently, a mild myopathy that originates from an underlying tendon and ligament pathology (which is a direct result of structural abnormalities to the collagen fibril architecture) has been demonstrated in this mouse model [Piróg & Briggs 2010, Piróg et al 2010].
MATN3
Gene structure. The coding sequence of MATN3 is organized into eight exons spanning approximately 21 kb. For a detailed summary of gene and protein information, see Table A, Gene.
Pathogenic variants (See Table 5.)
Table 5.
Pathogenic MATN3 Variants Discussed in This GeneReview
View in own window
DNA Nucleotide Change | Predicted Protein Change | Reference Sequences |
---|
c.209G>A | p.Arg70His |
NM_002381.4
NP_002372.1
|
c.359C>T | p.Thr120Met |
c.361C>T | p.Arg121Trp |
c.400G>A | p.Glu134Lys |
c.437T>G | p.Leu146Arg |
c.513_530del | p.Asp171_Glu176del |
c.518C>A | p.Ala173Asp |
c.575T>A | p.Ile192Asn |
c.581T>A | p.Val194Asp |
c.584C>A | p.Thr195Lys |
c.626G>C | p.Arg209Pro |
c.652T>A | p.Tyr218Asn |
c.656C>A | p.Ala219Asp |
c.659T>C | p.Val220Ala |
c.693G>C | p.Lys231Asn |
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of nomenclature.
Normal gene product. Matrilin-3, a protein of 486 amino acids, is the third member of a family of oligomeric multidomain ECM proteins comprising matrilin-1, -2, -3, and -4 [Wagener et al 2005]. The domain structure of the matrilin family of proteins is similar; each consists of:
Matrilins have been found in collagen-dependent and collagen-independent filament networks within the tissues in which they are expressed and may perform analogous functions in these different tissues. Matrilin-3 has been shown to interact with COMP and other cartilage collagens through the A domain [Mann et al 2004, Fresquet et al 2007, Fresquet et al 2008, Fresquet et al 2010].
Abnormal gene product.
MATN3 pathogenic variants appear to delay the folding of the A domain, which elicits an unfolded protein response and results in the retention of mutated matrilin-3 in the rER both in vitro [Cotterill et al 2005, Otten et al 2005] and in vivo [Leighton et al 2007, Nundlall et al 2010].
An MED mouse model harboring the p.Val194Asp pathogenic variant has demonstrated that the expression of this pathogenic variant causes ER stress and an unfolded protein response. Ultimately this results in a reduction in chondrocyte proliferation and dysregulated apoptosis [Leighton et al 2007, Nundlall et al 2010]. Interestingly, retained abnormal matrilin-3 forms non-native disulphide-bonded aggregates.